{
    "paper_id": "PMC7097811",
    "metadata": {
        "title": "Antivirals become a broader enterprise",
        "authors": [
            {
                "first": "Jeffrey",
                "middle": [
                    "L"
                ],
                "last": "Fox",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Selected antivirals in clinical trials\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Selected companies with antivirals in preclinical development\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: (a) Antivirals garner the largest share of the market (54%, $18 billion), with vaccines (30%, $19 billion) and mAbs (6%, $2 billion) getting smaller shares. (Source: Jain KK. Antiviral Therapeutics. Jain PharmaBiotech Publications, Basel, November 2007.) (b) 2006 US market share of anti-viral agents by indication (excluding HIV). (Source: Arrowhead Publications, Minneapolis, MN.)",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: HIV live cycle and points of intervention by antiviral drugs. Kim Caesar",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: (Source: The BBI Newsletter, ACH Media Publisher.)",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure 4: Modulating the host immune response with activators of TRLs is being tested as an approach to controlling viral infections.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {}
}